These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 7723278)

  • 1. Karyotype findings and molecular analysis of the bcr gene rearrangement supplementing the histologic classification of chronic myeloproliferative disorders.
    Werner M; Nolte M; Kaloutsi V; Buhr T; Kausche F; Georgii A
    Lab Invest; 1995 Apr; 72(4):405-10. PubMed ID: 7723278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence from molecular genetic and cytogenetic analyses that bone marrow histopathology is reliable in the diagnosis of chronic myeloproliferative disorders.
    Werner M; Kaloutsi V; Kausche F; Buhr T; Georgii A
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1993; 63(4):199-204. PubMed ID: 8099457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Histopathology and molecular pathology of chronic myeloproliferative disorders].
    Kreipe HH
    Veroff Pathol; 1993; 141():1-158. PubMed ID: 8372486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications.
    Panani AD
    Cancer Lett; 2007 Sep; 255(1):12-25. PubMed ID: 17383090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p190 bcr-abl rearrangement: a secondary cytogenetic event in some chronic myeloid disorders?
    Roumier C; Daudignon A; Soenen V; Dupriez B; Wetterwald M; Lai JL; Cosson A; Fenaux P; Preudhomme C
    Haematologica; 1999 Dec; 84(12):1075-80. PubMed ID: 10586207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia.
    Safley AM; Sebastian S; Collins TS; Tirado CA; Stenzel TT; Gong JZ; Goodman BK
    Genes Chromosomes Cancer; 2004 May; 40(1):44-50. PubMed ID: 15034867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cytogenetics and molecular studies confirm the histopathologic diagnosis of chronic myeloproliferative diseases].
    Werner M; Nolte M; Ewing M; Kaloutsi V; Kausche F; Georgii A
    Pathologe; 1995 Jan; 16(1):41-5. PubMed ID: 7886013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Karyotypic patterns in chronic myeloproliferative disorders: report on 74 cases and review of the literature.
    Mertens F; Johansson B; Heim S; Kristoffersson U; Mitelman F
    Leukemia; 1991 Mar; 5(3):214-20. PubMed ID: 2013980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. bcr gene rearrangement analysis in myeloproliferative disorders other than chronic myelogenous leukemia.
    Crisan D; Mattson JC; O'Malley BA; Schulz RW; Wilner F
    Cancer Detect Prev; 1996; 20(4):263-9. PubMed ID: 8818385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.
    Horn T; Kremer M; Dechow T; Pfeifer WM; Geist B; Perker M; Duyster J; Quintanilla-Martinez L; Fend F
    J Mol Diagn; 2006 Jul; 8(3):299-304. PubMed ID: 16825501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of a variant Ph1 translocation t(9;22;11) (q34;q11;q13) in chronic myelogenous leukemia (CML) reveals the translocation of the 3'-part of BCR gene to the chromosome band 11q13.
    Koduru PR; Goh JC; Pergolizzi RG; Lichtman SM; Broome JD
    Oncogene; 1993 Dec; 8(12):3239-47. PubMed ID: 8247527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
    Bock O
    Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The cellular and molecular-biological studies on Philadelphia chromosome-positive acute lymphocytic leukemia].
    Kunieda Y
    Hokkaido Igaku Zasshi; 1993 May; 68(3):337-49. PubMed ID: 8319933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloproliferative disorders. Classification and diagnostic features with special emphasis on chronic myelogenous leukemia and agnogenic myeloid metaplasia.
    Hyun BH; Gulati GL; Ashton JK
    Clin Lab Med; 1990 Dec; 10(4):825-38. PubMed ID: 2272176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytogenetics of agnogenic myeloid metaplasia: a study of 61 patients.
    Djordjevic V; Dencic-Fekete M; Jovanovic J; Bizic S; Jankovic G; Bogdanovic A; Cemerikic-Martinovic V; Gotic M
    Cancer Genet Cytogenet; 2007 Feb; 173(1):57-62. PubMed ID: 17284371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
    J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates.
    Patnaik MM; Knudson RA; Gangat N; Hanson CA; Pardanani A; Tefferi A; Ketterling RP
    Eur J Haematol; 2010 Jun; 84(6):518-24. PubMed ID: 20331734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia.
    Bacher U; Haferlach T; Kern W; Harich HD; Schnittger S; Haferlach C
    Cancer Genet Cytogenet; 2007 May; 175(1):52-6. PubMed ID: 17498558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in the P53 and RAS family genes are associated with tumor progression of BCR/ABL negative chronic myeloproliferative disorders.
    Gaidano G; Guerrasio A; Serra A; Carozzi F; Cambrin GR; Petroni D; Saglio G
    Leukemia; 1993 Jul; 7(7):946-53. PubMed ID: 8321046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
    Yin CC; Cortes J; Barkoh B; Hayes K; Kantarjian H; Jones D
    Cancer; 2006 Apr; 106(8):1730-8. PubMed ID: 16532439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.